These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1683221)

  • 1. [Treatment of hypertension and cardiovascular complications].
    Delahaye JP; Pillot M; Delahaye F; Dubost A
    Arch Mal Coeur Vaiss; 1991 Sep; 84 Spec No 3():117-21. PubMed ID: 1683221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Heart, brain and hypertension].
    Lüscher TF; Sturzenegger M; Noll G
    Schweiz Med Wochenschr; 1996 Aug; 126(34):1449-56. PubMed ID: 8848709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antihypertensive treatment and remission of left ventricular hypertrophy. Critical study].
    Clémenty J; Dulhoste MN; Bordier P; Lartigue MC; Pons N
    Arch Mal Coeur Vaiss; 1990 Dec; 83 Spec No 4():39-43. PubMed ID: 2150473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Do antihypertensive agents change the incidence of cardiovascular complications of hypertension?].
    Himbert D; Paillole C; Dahan M; Steg PG; Laperche T; Gourgon R
    Ann Cardiol Angeiol (Paris); 1991 Dec; 40(10):607-12. PubMed ID: 1685878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
    Ruskoaho H
    Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy of arterial hypertension. Reflections and suggestions].
    Franchi F; Fabbri G
    Clin Ter; 1989 May; 129(4):299-313. PubMed ID: 2527124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Can treatment of hypertension prevent myocardial infarction? New controlled clinical trials are proposed].
    Kjeldsen SE; Syvertsen JO; Lund-Johansen P
    Tidsskr Nor Laegeforen; 1993 Feb; 113(6):737-40. PubMed ID: 8096658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An evaluation of the therapeutic trials aimed at regression of ventricular hypertrophy in arterial hypertension].
    Clémenty J; Dulhoste MN; Bordier P; Lartigue MC; Pons N
    Ann Cardiol Angeiol (Paris); 1991 Oct; 40(8):503-8. PubMed ID: 1836942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
    Hansson L
    J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic trials in arterial hypertension].
    Gueyffier F
    Rev Prat; 1999 Mar; 49(5):512-8. PubMed ID: 10358401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension].
    Román O; Cuevas G; Bunout D
    Rev Med Chil; 1998 Jul; 126(7):745-52. PubMed ID: 9830766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.